• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Cabozantinib improves progression-free survival in patients with metastatic papillary renal cell carcinoma

byNeel MistryandTeddy Guo
June 25, 2021
in Chronic Disease, Nephrology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. Progression-free survival was longer in patients in the cabozantinib group (9.0 months) than in the sunitinib group (5.6 months).

2. Occurrence of grade 3 or 4 adverse events were similar among patients in the cabozantinib and sunitinib groups.

Evidence Rating Level: 1 (Excellent)

Study Rundown: Papillary renal cell carcinoma (PRCC) is among the most severe forms of kidney cancer, comprising of one or more mutations in the MET (hepatocyte growth factor receptor) oncogene. Currently, the standard of care for patients with advanced or metastatic PRCC is a vascular endothelial growth factor (VEGF) inhibitor, sunitinib. However, studies suggest that MET inhibitors, such as cabozantinib, crizotinib, and savolitinib, may have beneficial effects and should be tested further. This multicenter, randomized controlled trial aimed to compare sunitinib with MET kinase inhibitors cabozantinib, crizotinib, and savolitinib for treatment of patients with PRCC. The primary endpoint for this study was progression free survival (PFS), while secondary endpoints included toxicity, objective response rate, and overall survival from baseline. According to study results, PFS was longer among patients in the cabozantinib group than in the sunitinib group. However, treatment with savolitinib and crizotinib did not improve PFS compared to sunitinib. This study was limited by a relatively small sample size since only 147 patients were included in the intention-to-treat analysis. Nevertheless, it provides valuable insight into the use of targeted therapy over an existing standard of care in patients with metastatic PRCC.

Click to read the study in The Lancet

Relevant Reading: Efficacy of Savolitinib vs Sunitinib in Patients With MET-Driven Papillary Renal Cell Carcinoma – The SAVOIR Phase 3 Randomized Controlled Trial

In-depth [randomized controlled trial]: Between Apr 5, 2016, and Dec 15, 2019, 152 patients were enrolled across 65 centers in the USA and Canada. Included patients were those ≥ 18 years of age with metastatic PRCC who received up to one previous systemic therapy (excluding vascular endothelial growth factor-directed and MET-directed agents). Patients with severe intercurrent illness or contraindications to study medications were excluded. Altogether, 147 patients (46 in sunitinib, 44 in cabozantinib, 28 in crizotinib, and 29 in savolitinib) were included in analysis. Among enrolled patients, the median age was 66 years (interquartile range [IQR] 58-75) and 76% (112 of 147) were male.

RELATED REPORTS

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer

The primary endpoint concerning median PFS was significantly greater in the cabozantinib group (median 9.0 months, 95% confidence interval [CI] 5.6-12.4) compared to the sunitinib group (median 5.6 months, 95% CI 2.9-6.7, hazard ratio [HR] 0.60, 95% CI 0.37-0.97, p=0.019). Crizotinib (median 2.8 months, 95% CI 2.6-3.6) and savolitinib (median 3.0 months, 95% CI 2.8-7.2) did not improve PFS compared with sunitinib. The secondary endpoint of objective response rate was higher with cabozantinib (23%) than sunitinib (4%), crizotinib (0%), and savolitinib (3%). Similarly, median overall survival was greater for the cabozantinib group (20.0 months) than the sunitinib group (16.4 months), although this difference was not significant (HR 0.84, 95% CI 0.47-1.51). Grade 3 or 4 adverse events were seen in 69% (n=31) of patients in the sunitinib group and 74% (n=32) of patients in the cabozantinib group. In contrast, only 37% (n=10) in the crizotinib group and 39% (n=11) in the savolitinib group experienced grade 3 or 4 treatment-related outcomes. Findings from this study suggest that use of cabozantinib may improve progression-free survival compared to sunitinib in patients with metastatic papillary renal cell carcinoma. Further studies should be done to evaluate the efficacy of crizotinib and savolitinib.

Image: PD

©2021 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: cabozantinibCrizotinibMET inhibitorsoncologypapillary renal cell carcinomapapillary renal cell carcinoma (PRCC)renal cell neoplasmrenal-cell carcinomasavolitinibsunitinib
Previous Post

#VisualAbstract CASTOR trial follow-up: Health-related quality of life was maintained in patients treated with daratumumab, bortezomib, and dexamethasone over time for relapsed or refractory multiple myeloma

Next Post

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

RelatedReports

Benefits of high-intensity surveillance following colorectal adenoma removal likely outweigh costs
Chronic Disease

Adenoma detection rate is inversely associated with post-colonoscopy colorectal cancer risk

March 20, 2023
Proton radiotherapy may be effective for refractory pituitary adenomas
Chronic Disease

Pituitary microadenomas exhibit slow growth and may require less frequent MRI surveillance

March 18, 2023
Nivolumab may be effective in platinum-resistant ovarian cancer
Gastroenterology

Addition of PD-L1 inhibitor may improve outcomes in neoadjuvant therapy for esophageal cancer

March 15, 2023
Macitentan better than placebo for preventing progression of pulmonary arterial hypertension [SERAPHIN Trial]
Chronic Disease

Sotorasib superior to docetaxel for treatment of KRASG12C-positive non-small-cell lung cancer

March 14, 2023
Next Post
#VisualAbstract: Cemiplimab monotherapy significantly improves outcomes in patients with advanced non-small-cell lung cancer with PD-L1 of at least 50%

#VisualAbstract: Relugolix combination therapy led to reduction in uterine fibroid symptoms

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

#VisualAbstract OAsIS: Ibrutinib, obinutuzumab, and venetoclax was well-tolerated and showed high response rates in both untreated and relapsed mantle cell lymphoma

Many new pediatric asthma cases attributable to obesity

Food security status lower effectiveness of lifestyle-based weight loss approaches

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Specific histopathologic renal lesions may be associated with increased risk of cardiovascular disease
  • Symptom and viral relapse more common in COVID-19 patients without antiviral treatment
  • The Scan by 2 Minute Medicine®: Endometriosis Awareness Month, OnlineMedEd Charges, Canadian Grocery Store Controversy, BetterHelp’s Privacy Concerns
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options